PALO ALTO, CA--(Marketwired - Mar 10, 2014) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the publication of the IMPACT-PCP (Investigation ...

The true incidence of obstructive coronary artery disease (CAD) among patients undergoing transcatheter aortic valve implantation (TAVI) is not known Assessment of CAD using angiography only can ...

PALO ALTO, Calif.--(BUSINESS WIRE)--CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced online publication of a study in the American Heart Journal. The paper ...

WASHINGTON, DC—Coronary CT angiography (CCTA) seems to have the edge over functional testing for the assessment of suspected CAD in patients with newly diagnosed type 2 diabetes, real-world data show.

Researchers have completed an observational validation study of a new genomic test for obstructive coronary artery disease for patients presenting with stable chest pain, but will release results ...

Please provide your email address to receive an email when new articles are posted on . A low score on a blood test that evaluates age, sex and gene expression may help to rule out the presence of ...

CardioDx Also Separately Raises $20 Million in New Financing to Support the Company's Commercial Growth and Operations CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular ...

LONDON, UK — Taking a few extra minutes to perform carotid-artery ultrasound alongside stress echocardiography in patients with suspected coronary artery disease (CAD) offers incremental prognostic ...

Quest Diagnostics Inc.DGX recently entered into a national specimen-draw agreement with CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics. Per the agreement, both ...

BALTIMORE, MD—In patients with chest pain who are at high risk for CAD but have no known disease, evaluation with coronary CT angiography (CTA) is associated with an improvement in long-term outcomes ...